Shanghai Henlius Biotech Inc

Sidike, stock code 300806, plans to have its wholly owned subsidiary Xingyuantai implement the construction of an annual production capacity of 103,000 tonnes of high-end functional BOPET base film expansion project, with a total investment of about 1.652 billion yuan. The project will mass-produce MLCC release film base film, polarizer release and protective film base film, and other series of high-end functional BOPET substrate products, mainly serving downstream fields such as microelectronic MLCC manufacturing, specialty optical devices, and precision PCB circuits. In other company news on the same day, Huaqin Technology said its supernode products achieved first shipment in the second quarter and entered a rapid volume ramp-up phase in the third quarter. Yibo Technology's wholly owned subsidiary Zhuhai Yibo Electronics plans to add investment in the second phase of a PCB board plant project, with total new investment not exceeding 800 million yuan. Xingyun Technology's wholly owned subsidiary Changsha Xiangshuyun Technology signed an intelligent computing resource leasing service contract with a VE customer, with a tax-inclusive total amount of 872 million yuan. In addition, Fosun Pharma's controlling subsidiary Henlius signed a collaboration and license agreement with Amberstone, obtaining exclusive licenses for two T-cell engager products, and will pay upfront payments, research and development expenses, and development and regulatory milestone payments totaling up to 236 million US dollars, plus sales milestone payments of up to 652 million US dollars.

Sandoz has unveiled an ambitious growth strategy, dubbed Bio100, aiming to become the undisputed leader in the biosimilar industry by 2040, with a portfolio of more than 100 biosimilars. Announced at its Capital Markets Day on 8 September, the plan targets a 'golden decade' for biosimilars, leveraging the industry's patent cliff. CEO Richard Saynor said the window of opportunity is wide open, and the company plans to more than double net sales over the next decade. Chief commercial officer Rebecca Guntern highlighted an 'unparalleled opportunity' from loss of exclusivity, with over $300bn in originator sales not yet targeted. Key growth drivers include GLP-1 receptor agonists, monoclonal antibodies, and antibody drug conjugates, with a $322m partnership with China's Henlius and a $300m investment in a new facility in Slovenia supporting the strategy.

Henlius Executive Director and CEO Zhu Jun said at the interim results briefing on August 24 that volume-based procurement of biosimilars may not be a challenge but could be an opportunity. In the first half of this year, Henlius achieved revenue of 3.588 billion yuan, up 27.3 percent year on year, and net profit of 430 million yuan, up 10.3 percent year on year. The company already has 10 products approved for marketing in more than 60 countries and regions worldwide. In the first half of 2026, global product sales revenue reached 2.9386 billion yuan, up 14.9 percent year on year, of which overseas product sales revenue surged 159.4 percent year on year to 105.3 million yuan. Zhu Jun said the company began actively preparing for biosimilar volume-based procurement several years ago, on the one hand continuously optimizing production processes to reduce manufacturing costs, and on the other hand seeking new sales growth, including stepping up innovative drugs and accelerating overseas expansion.

Sandoz has entered a collaboration agreement with Shanghai Henlius Biotech to develop up to 10 biosimilars, with total milestone payments of up to $322 million. The deal includes near-term payments of up to $100.5 million for initial assets, and Henlius will develop and manufacture the products while Sandoz handles commercialization worldwide except China. The initial assets include biosimilars referencing Erbitux, Repatha, and Benlysta, as well as a recombinant human hyaluronidase in technical development. Sandoz's biosimilar pipeline now stands at 39 assets, with potential to reach 46, and the company says the agreement supports its strategy to capture a significant share of the biosimilar loss-of-exclusivity market over the next decade.

Fosun Pharma's controlling subsidiary Henlius has received approval from the National Medical Products Administration to conduct clinical trials of HLX43 in combination with bevacizumab, with or without chemotherapy, for advanced or metastatic solid tumors. HLX43 is an ADC drug developed by Henlius using a novel DNA topoisomerase I inhibitor small-molecule toxin-peptide linker conjugated with its self-developed anti-PD-L1 antibody.

Hisoar Pharmaceutical disclosed an earnings forecast, expecting a net loss attributable to the parent of 50 million to 75 million yuan in the first half of 2026, compared with a profit of 14.0937 million yuan in the same period last year. The net loss after deducting non-recurring items is expected to be 110 million to 135 million yuan, compared with a profit of 19.2833 million yuan in the same period last year. The company stated that the pharmaceutical segment incurred a loss due to continued losses in the penem series and declining gross margins for other products, along with asset impairment provisions. The dye segment saw growth in revenue and gross margin. Meanwhile, the depreciation of the US dollar against the renminbi had a significant negative impact on net profit. In addition, non-recurring gains and losses are expected to contribute approximately 60 million yuan, mainly from the increase in the valuation of indirectly held shares of Henlius and dividends from investee companies.

Organon Canada and Shanghai Henlius Biotech have launched BILDYOS and TUZEMTY, biosimilars to PROLIA and XGEVA respectively, in Canada for all indications of the reference products. The two denosumab injection treatments address osteoporosis and bone events associated with cancer, expanding Organon's Canadian biosimilars portfolio to eight products across five therapeutic areas. Dominic Bégin, President and Managing Director at Organon Canada, said the approvals represent an important step toward broadening access to bone-care treatments, noting that osteoporosis affects 2.3 million Canadians. The launch follows a 2022 license and supply agreement granting Organon exclusive commercialization rights to several Henlius biosimilars outside of China.